{"title": "Biosimilar insulin lispro shown not inferior to Humalog\u00ae in efficacy or safety", "text": "", "article_link": null, "url": "http://www.eurekalert.org/pub_releases/2017-08/mali-bil080917.php", "region": "namerica", "source_link": null, "funder": "", "meeting": "", "institution": "Mary Ann Liebert, Inc./Genetic Engineering News", "keywords": ["Medicine/Health", " Metabolism/Metabolic Diseases", " Diabetes"], "journal": "Diabetes Technology & Therapeutics", "description": "A study comparing the safety and efficacy of SAR342434, a biosimilar (follow-on form) of insulin lispro-Humalog\u00ae, found it to be comparable to that of the brand name drug in patients also using insulin glargine.", "date": "Wed, 09 Aug 2017 04:00:00 GMT"}